Cargando…

Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab

BACKGROUND: The aim of this study was to investigate the effect of intravitreal anti-vascular endothothelial growth factor (VEGF) injection on intraocular pressure (IOP) and mean ocular perfusion pressure (MOPP). METHODS: MOPP results were obtained by measuring mean arterial pressure (MAP) and IOP j...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jong Wook, Park, Hoon, Choi, Jeong Han, Lee, Hyun Joo, Moon, Sang Woong, Kang, Ja Heon, Kim, Young Gyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886436/
https://www.ncbi.nlm.nih.gov/pubmed/27245159
http://dx.doi.org/10.1186/s12886-016-0255-8
_version_ 1782434618750795776
author Lee, Jong Wook
Park, Hoon
Choi, Jeong Han
Lee, Hyun Joo
Moon, Sang Woong
Kang, Ja Heon
Kim, Young Gyun
author_facet Lee, Jong Wook
Park, Hoon
Choi, Jeong Han
Lee, Hyun Joo
Moon, Sang Woong
Kang, Ja Heon
Kim, Young Gyun
author_sort Lee, Jong Wook
collection PubMed
description BACKGROUND: The aim of this study was to investigate the effect of intravitreal anti-vascular endothothelial growth factor (VEGF) injection on intraocular pressure (IOP) and mean ocular perfusion pressure (MOPP). METHODS: MOPP results were obtained by measuring mean arterial pressure (MAP) and IOP just before the injection, immediately after the injection, at 30 min, 1 day, and 1 week after injection from 65 eyes of 42 patients. RESULTS: Pre-injection mean IOP was 16.66 ± 3.50 mmHg, and mean IOP was 43.81 ± 9.69 mmHg immediately after the injection, 17.57 ± 4.44 mmHg at 30 min, 15.00 ± 4.21 mmHg at 1 day, and 15.90 ± 3.63 mmHg at 1 week after the injection. Pre-injection mean MOPP was 46.39 ± 5.78 mmHg, and mean MOPP was 25.14 ± 8.79 mmHg immediately after the injection, 45.87 ± 6.31 mmHg at 30 min, 46.93 ± 6.25 mmHg at 1 day, and 46.50 ± 4.94 mmHg at 1 week after the injection. CONCLUSION: The instant increase in IOP by intravitreal anti-VEGF injection led to a transient decrease in MOPP. Based on this finding, the instant increase in IOP after intravitreal anti-VEGF injection does not significantly impair retinal blood flow.
format Online
Article
Text
id pubmed-4886436
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48864362016-06-01 Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab Lee, Jong Wook Park, Hoon Choi, Jeong Han Lee, Hyun Joo Moon, Sang Woong Kang, Ja Heon Kim, Young Gyun BMC Ophthalmol Research Article BACKGROUND: The aim of this study was to investigate the effect of intravitreal anti-vascular endothothelial growth factor (VEGF) injection on intraocular pressure (IOP) and mean ocular perfusion pressure (MOPP). METHODS: MOPP results were obtained by measuring mean arterial pressure (MAP) and IOP just before the injection, immediately after the injection, at 30 min, 1 day, and 1 week after injection from 65 eyes of 42 patients. RESULTS: Pre-injection mean IOP was 16.66 ± 3.50 mmHg, and mean IOP was 43.81 ± 9.69 mmHg immediately after the injection, 17.57 ± 4.44 mmHg at 30 min, 15.00 ± 4.21 mmHg at 1 day, and 15.90 ± 3.63 mmHg at 1 week after the injection. Pre-injection mean MOPP was 46.39 ± 5.78 mmHg, and mean MOPP was 25.14 ± 8.79 mmHg immediately after the injection, 45.87 ± 6.31 mmHg at 30 min, 46.93 ± 6.25 mmHg at 1 day, and 46.50 ± 4.94 mmHg at 1 week after the injection. CONCLUSION: The instant increase in IOP by intravitreal anti-VEGF injection led to a transient decrease in MOPP. Based on this finding, the instant increase in IOP after intravitreal anti-VEGF injection does not significantly impair retinal blood flow. BioMed Central 2016-05-31 /pmc/articles/PMC4886436/ /pubmed/27245159 http://dx.doi.org/10.1186/s12886-016-0255-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lee, Jong Wook
Park, Hoon
Choi, Jeong Han
Lee, Hyun Joo
Moon, Sang Woong
Kang, Ja Heon
Kim, Young Gyun
Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
title Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
title_full Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
title_fullStr Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
title_full_unstemmed Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
title_short Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
title_sort short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886436/
https://www.ncbi.nlm.nih.gov/pubmed/27245159
http://dx.doi.org/10.1186/s12886-016-0255-8
work_keys_str_mv AT leejongwook shorttermchangesofintraocularpressureandocularperfusionpressureafterintravitrealinjectionofbevacizumaborranibizumab
AT parkhoon shorttermchangesofintraocularpressureandocularperfusionpressureafterintravitrealinjectionofbevacizumaborranibizumab
AT choijeonghan shorttermchangesofintraocularpressureandocularperfusionpressureafterintravitrealinjectionofbevacizumaborranibizumab
AT leehyunjoo shorttermchangesofintraocularpressureandocularperfusionpressureafterintravitrealinjectionofbevacizumaborranibizumab
AT moonsangwoong shorttermchangesofintraocularpressureandocularperfusionpressureafterintravitrealinjectionofbevacizumaborranibizumab
AT kangjaheon shorttermchangesofintraocularpressureandocularperfusionpressureafterintravitrealinjectionofbevacizumaborranibizumab
AT kimyounggyun shorttermchangesofintraocularpressureandocularperfusionpressureafterintravitrealinjectionofbevacizumaborranibizumab